Bo Yu

Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma

M. Kudo, N. Nishida, L. Rimassa, 2021, Liver Cancer.

Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.

K. Goldberg, R. Pazdur, L. Rimassa, 2021, European journal of cancer.

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

L. Rimassa, N. Personeni, T. Pressiani, 2020, Journal for ImmunoTherapy of Cancer.

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

L. Rimassa, N. Personeni, T. Pressiani, 2020, Journal for ImmunoTherapy of Cancer.

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

L. Rimassa, N. Personeni, T. Pressiani, 2020, Cancers.

Treatment-related toxicity predicts for improved outcome in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitor therapy

L. Rimassa, N. Personeni, T. Pressiani, 2020, Journal of Hepatology.

Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study

J. Liu, C. Yi, Fei Ding, 2023, Frontiers in Oncology.

Abstract 485: Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study

M. Kudo, N. Nishida, L. Rimassa, 2021, Clinical Research (Excluding Clinical Trials).